A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Public ClinicalTrials.gov record NCT05499130. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical remission (UC) and endoscopic response (CD) at week 14. Secondary objectives: * To evaluate the efficacy of 2 different doses of TEV-48574 as assessed by multiple standard measures * To evaluate the safety and tolerability of 2 different doses of TEV-48574 * To evaluate the immunogenicity of 2 different dioses of TEV-48574 The study will consist of a screening period of up to 6 weeks (42 days), a 14-week treatment period, and a 4-week follow-up period.
Study identification
- NCT ID
- NCT05499130
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 290 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2022 (Actual)
- Primary completion
- Nov 12, 2024 (Actual)
- Completion
- Nov 12, 2024 (Actual)
- Last update posted
- Mar 27, 2026
2022 – 2024
United States locations
- U.S. sites
- 36
- U.S. states
- 18
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 15568 | Sun City | Arizona | 85351 | — |
| Teva Investigational Site 15556 | San Diego | California | 92103 | — |
| Teva Investigational Site 15747 | San Diego | California | 92103 | — |
| Teva Investigational Site 15357 | Kissimmee | Florida | 34741 | — |
| Teva Investigational Site 15563 | Miami | Florida | 33032 | — |
| Teva Investigational Site 15365 | Miami | Florida | 33136 | — |
| Teva Investigational Site 15748 | Miami | Florida | 33176 | — |
| Teva Investigational Site 15375 | Orlando | Florida | 32803 | — |
| Teva Investigational Site 15359 | Pinellas Park | Florida | 33781 | — |
| Teva Investigational Site 15566 | Glenview | Illinois | 60026 | — |
| Teva Investigational Site 15567 | Gurnee | Illinois | 60031 | — |
| Teva Investigational Site 15574 | New Albany | Indiana | 47150 | — |
| Teva Investigational Site 15362 | Iowa City | Iowa | 52242 | — |
| Teva Investigational Site 15367 | Kansas City | Kansas | 66160 | — |
| Teva Investigational Site 15368 | Louisville | Kentucky | 40202 | — |
| Teva Investigational Site 15575 | Louisville | Kentucky | 40218 | — |
| Teva Investigational Site 15363 | Columbia | Maryland | 21045 | — |
| Teva Investigational Site 15358 | Liberty | Missouri | 64068 | — |
| Teva Investigational Site 15373 | St Louis | Missouri | 63110 | — |
| Teva Investigational Site 15369 | Las Vegas | Nevada | 89128. | — |
| Teva Investigational Site 15558 | North Massapequa | New York | 11758 | — |
| Teva Investigational Site 15370 | Chapel Hill | North Carolina | 27514 | — |
| Teva Investigational Site 15750 | Beavercreek | Ohio | 45440 | — |
| Teva Investigational Site 15557 | Greenville | South Carolina | 29607 | — |
| Teva Investigational Site 15573 | Cordova | Tennessee | 38018 | — |
| Teva Investigational Site 15360 | Austin | Texas | 78748 | — |
| Teva Investigational Site 15371 | Dallas | Texas | 75246 | — |
| Teva Investigational Site 15569 | Garland | Texas | 75044 | — |
| Teva Investigational Site 15559 | Harlingen | Texas | 78550 | — |
| Teva Investigational Site 15366 | Katy | Texas | 77494 | — |
| Teva Investigational Site 15743 | Lubbock | Texas | 79424 | — |
| Teva Investigational Site 15372 | Pearland | Texas | 77584 | — |
| Teva Investigational Site 15374 | San Antonio | Texas | 78229 | — |
| Teva Investigational Site 15565 | Southlake | Texas | 76092 | — |
| Teva Investigational Site 15361 | Tyler | Texas | 75701 | — |
| Teva Investigational Site 15364 | Salt Lake City | Utah | 84124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 128 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05499130, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05499130 live on ClinicalTrials.gov.